Akoya Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Akoya Biosciences, Inc. (Nasdaq: AKYA), known as The Spatial Biology Company®, will participate virtually in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 1 p.m. ET. CEO Brian McKelligon and CFO Joe Driscoll will present during this event, which is exclusive to BTIG clients. Akoya focuses on spatial phenotyping, providing cutting-edge single-cell imaging solutions to enhance research in discovering and treating diseases. More details about Akoya’s solutions can be found at www.akoyabio.com.

News Market Reaction – AKYA

-2.93%

-2.93% Session move

In the trading session that priced this news, AKYA declined 2.93%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MARLBOROUGH, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company^®, today announced that it will be virtually participating in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Brian McKelligon, CEO, and Joe Driscoll, CFO, are scheduled to present on Tuesday, February 15^th, 2022 at 1 p.m. ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Akoya Biosciences
As The Spatial Biology Company^®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com

Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com

FAQ

When is Akoya's presentation at the BTIG conference?

Akoya Biosciences will present on February 15, 2022, at 1 p.m. ET during the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Who will represent Akoya Biosciences at the BTIG conference?

CEO Brian McKelligon and CFO Joe Driscoll are scheduled to represent Akoya Biosciences during the presentation.

What is the focus of Akoya Biosciences?

Akoya Biosciences specializes in spatial phenotyping and provides advanced single-cell imaging solutions for research in biology and human health.

How can I listen to Akoya's presentation at the BTIG conference?

To listen to the live event, interested parties must contact their BTIG representative.

What is the ticker symbol for Akoya Biosciences?

The ticker symbol for Akoya Biosciences is AKYA, listed on Nasdaq.